Faculty Bibliography

Cognitive dysfunction in Parkinson's disease (PD) is associated with increased expression of the PD cognition-related pattern (PDCP), which overlaps with the normal default mode network (DMN). Here, we sought to determine the degree to which the former network represents loss of the latter as a manifestation of the disease process. To address this, we first analyzed metabolic images (fluorodeoxyglucose positron emission tomography [PET]) from a large PD sample with varying cognitive performance. Cognitive impairment in these patients correlated with increased PDCP expression as well as DMN loss. We next determined the spatial relationship of the 2 topographies at the subnetwork level. To this end, we analyzed resting-state functional magnetic resonance imaging (rs-fMRI) data from an independent population. This approach uncovered a significant PD cognition-related network that resembled previously identified PET- and rs-fMRI-based PDCP topographies. Further analysis revealed selective loss of the ventral DMN subnetwork (precuneus and posterior cingulate cortex) in PD, whereas the anterior and posterior components were not affected by the disease. Importantly, the PDCP also included a number of non-DMN regions such as the dorsolateral prefrontal and medial temporal cortex. The findings show that the PDCP is a reproducible cognition-related network that is topographically distinct from the normal DMN.

INTRODUCTION/BACKGROUND:Neonates with severe Pierre Robin sequence (PRS) can be treated by mandibular distraction osteogenesis (MDO), tongue-lip adhesion, or tracheostomy; however, there is an active debate regarding the indications of MDO in this patient population. Published algorithms identify tracheomalacia, bronchomalacia, laryngomalacia, hypotonic syndromes, and central sleep apnea as contraindications for MDO and indications for tracheostomy, but these comorbidities may exist along a spectrum of severity. The authors propose that appropriately selected neonates with PRS who concurrently express 1 or more of these traditional contraindications may be successfully treated with MDO. METHODS:The authors performed a 5-year retrospective chart review of all neonates who underwent MDO for treatment of severe PRS. All patients expressed a comorbidity previously identified as an indication for tracheostomy. Pre- and postoperative characteristics were recorded. Apnea/hypopnea index (AHI) before and after MDO were compared using 2-tailed repeated measures t-test. RESULTS:The authors identified 12 patients with severe PRS and conditions associated with contraindications to MDO: 9 (75.0%) patients had laryngomalacia, 6 (50.0%) patients had tracheomalacia, 2 (16.6%) patients had bronchomalacia, 1 (8.3%) patient had central sleep apnea, and 3 (25.0%) patients had hypotonia. Five (41.7%) patients underwent concurrent gastrostomy tube placement due to feeding insufficiency. Average birthweight was 3.0 kg. Average pre-op AHI was 34.8. Average post-op AHI was 7.3. All patients successfully underwent MDO with avoidance of tracheostomy. CONCLUSIONS:By employing an interdisciplinary evaluation of patient candidacy, MDO can safely and effectively treat upper airway obstruction and avoid tracheostomy in higher-risk neonatal patients with traditional indications for tracheostomy.

PURPOSE:This study characterizes the association of risk factors including race, ethnicity, and insurance status with presenting visual acuity (VA) and diabetic retinopathy (DR) severity in patients initiating treatment with anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). DESIGN:Retrospective, cross-sectional study. PARTICIPANTS:The Academy Intelligent Research in Sight (IRIS) Registry database was queried for patients who initiated anti-VEGF injection treatment for DME between 2012 and 2020 (n = 203 707). METHODS:Multivariate regression analyses were conducted to understand how race, ethnicity, insurance status, and geographic location were associated with baseline features. MAIN OUTCOME MEASURES:Visual acuity and DR severity. RESULTS:Patients on Medicare and private insurance presented with higher baseline VA compared with patients on Medicaid (median of 2.31 and 4.17 greater Early Treatment Diabetic Retinopathy Scale [ETDRS] letters, respectively P < 0.01). White and non-Hispanic patients presented with better VA compared with their counterparts (median of 0.68 and 2.53 greater ETDRS letters, respectively; P < 0.01). Black and Hispanic patients presented with a worse baseline DR severity compared with White and non-Hispanic patients (odds ratio, 1.23 and 1.71, respectively; P < 0.01). CONCLUSIONS:There are ethnic and insurance-based disparities in VA and disease severity upon initiation of anti-VEGF therapy for DME treatment. Public health initiatives could improve timely initiation of treatment.

Background: Although a more aggressive disease course has been reported in African-American (AA) patients with multiple sclerosis (MS) in comparison with Caucasian (CA) patients, differences in disability outcomes might be partly related to socioeconomic factors limiting access to cure or influencing lifestyle choices.
Aim(s): To assess the impact of demographics, socioeconomic status and comorbidities on disability differences between AA and CA MS patients.
Method(s): As part of an ongoing longitudinal study, 120 MS patients (60 AA, 60 CA) and 82 HC (43 AA, 39 CA) were prospectively enrolled. All subjects included in the study self-identified as AA or CA. Data on demographic, socioeconomic and clinical status of all subjects were collected. Differences in disability scales between AA and CA MS patients were assessed via ordinal logistic or multivariable linear regression, as appropriate, entering in the final model demographic features (age, gender), indirect indicators of socioeconomic status (educational level, body mass index) and comorbidities.
Result(s): No difference in disease management (diagnostic delay, number of therapeutic switches, treatment with first or second line disease modifying therapies) was present between the two groups. No differences in strength, sensitivity, balance and verbal fluency were detected between AA and CA MS patients. Differences in Expanded Disability Status Scale, walking endurance and verbal memory disappeared in the models including socioeconomic status and comorbidities. On the contrary, even in complex models accounting for confounders, AA showed higher Multiple Sclerosis Severity Score (3.17 vs 1.96, p=0.017), worse manual dexterity (9-hole peg test 25.34 vs 22.44, p=0.005; grooved pegboard test 12.65 vs 15.02, p=0.001; finger tapping test non dominant hand 48.53 vs 52.94, p=0.009), and worse cognitive performance in the attentional, visuospatial and executive domains (symbol digit modality test 50.82 vs 56.78, p=0.014; multitasking test 3.93 vs 5.13, p=0.002; brief visuospatial memory test 16.43 vs 20.90, p<0.001; Stroop test 37.76 vs 44.29, p=0.020).
Conclusion(s): AA patients with MS present a more severe disability status than CA patients. Observed differences are only partly accounted for by sociodemographic factors

The COVID-19 pandemic has had an unprecedented impact on people and healthcare services. The disruption to chronic illnesses, such as epilepsy, may relate to several factors ranging from direct infection to secondary effects from healthcare reorganization and social distancing measures.

Background and aims: Epilepsy encompasses a group of neurological disorders characterized by an imbalance of electrical activity in the central nervous system (CNS) and recurrent seizures representing the principal clinical manifestation. Acetylcholine (ACh), serotonin, and norepinephrine (NE) may modulate neural activity via several mechanisms, mainly through its receptors/transporter activity and alterations in the extracellular potassium (K⁺) concentration via inwardly rectifying K⁺ (Kir) channels. Therefore, the aim of this study was to investigate the immunoreactivity pattern of these neurotransmitter, receptors/transporters and Kir channels in Pentylenetetrazol (PTZ)-kindling rat model, a well-established tool for studying chronic epilepsy.
Method(s): Kindling was chemically induced by intraperitoneally injections of PTZ for one month. Changes in the immunoreactivity of epileptogenesis-related neurotransmitter receptors/transporters (M2, 5-HT2B, and NE transporter) as well as Kir3.1 and Kir6.2 channels were determined in the cortex, hippocampus and medulla of adult Wistar rats by immunohistochemistry analyses.
Result(s): Increased immunoreactivity of the NE transporter, M2, and 5-HT2B receptors was witnessed in the cortex and medulla. While the immunoreactivity of the 5-HT2B receptor was found increased in the cortex and medulla, it was decreased in the hippocampus, with no changes observed in the M2 receptor in this region. Kir3.1 and Kir6.2 staining showed increase immunoreactivity in the cerebral cortex, but contrasting findings were found in the hippocampus and medulla.
Conclusion(s): Our data suggested significant changes in the neurotransmitter, receptors/transporters and ion channels, that may regulate neurotransmitter levels such as ACh, serotonin, and NE in the cortex, hippocampus, and medulla, thus contributing to epileptogenesis.
Copyright

Traumatic brain injury (TBI) is one of the main causes of death worldwide. It is a complex injury that influences cellular physiology, causes neuronal cell death, and affects molecular pathways in the brain. This in turn can result in sensory, motor, and behavioral alterations that deeply impact the quality of life. Repetitive mild TBI can progress into chronic traumatic encephalopathy (CTE), a neurodegenerative condition linked to severe behavioral changes. While current animal models of TBI and CTE such as rodents, are useful to explore affected pathways, clinical findings therein have rarely translated into clinical applications, possibly because of the many morphofunctional differences between the model animals and humans. It is therefore important to complement these studies with alternative animal models that may better replicate the individuality of human TBI. Comparative studies in animals with naturally evolved brain protection such as bighorn sheep, woodpeckers, and whales, may provide preventive applications in humans. The advantages of an in-depth study of these unconventional animals are threefold. First, to increase knowledge of the often-understudied species in question; second, to improve common animal models based on the study of their extreme counterparts; and finally, to tap into a source of biological inspiration for comparative studies and translational applications in humans.